Labiana Health（LAB）株式概要Labiana Health, S.A.は、スペイン、欧州連合（EU）域内、および国際的に、動物用医薬品およびヒト用医薬品の開発、製造、販売、マーケティングを行っている。 詳細LAB ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長5/6過去の実績2/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より77.7%で取引されている 収益は年間54.61%増加すると予測されています 今年は黒字化を達成 リスク分析利払いは収益で十分にカバーされない Spanish市場と比較して、過去 3 か月間の株価の変動が非常に大きい財務結果に影響を与える大きな一時的項目 最新の財務報告は6か月以上前のものである +2 さらなるリスクすべてのリスクチェックを見るLAB Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€6.903.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m106m2016201920222025202620282031Revenue €105.8mEarnings €1.3mAdvancedSet Fair ValueView all narrativesLabiana Health, S.A. 競合他社Laboratorio Reig JofreSymbol: BME:RJFMarket cap: €223.1mFaes FarmaSymbol: BME:FAEMarket cap: €1.5bAlmirallSymbol: BME:ALMMarket cap: €2.5bLaboratorios Farmaceuticos RoviSymbol: BME:ROVIMarket cap: €3.1b価格と性能株価の高値、安値、推移の概要Labiana Health過去の株価現在の株価€6.9052週高値€8.2052週安値€3.14ベータ0.171ヶ月の変化2.22%3ヶ月変化54.02%1年変化100.58%3年間の変化130.00%5年間の変化n/aIPOからの変化50.00%最新ニュースNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$64.3m).Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €5.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 27x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 97% over the past three years.お知らせ • Apr 18Labiana Health, S.A. to Report Fiscal Year 2025 Results on Apr 21, 2026Labiana Health, S.A. announced that they will report fiscal year 2025 results on Apr 21, 2026New Risk • Apr 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€38.7m market cap, or US$45.5m).Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €4.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 68% over the past three years.最新情報をもっと見るRecent updatesNew Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$64.3m).Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €5.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 27x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 97% over the past three years.お知らせ • Apr 18Labiana Health, S.A. to Report Fiscal Year 2025 Results on Apr 21, 2026Labiana Health, S.A. announced that they will report fiscal year 2025 results on Apr 21, 2026New Risk • Apr 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€38.7m market cap, or US$45.5m).Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €4.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 44% over the past three years.Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 68% over the past three years.New Risk • Feb 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€31.9m market cap, or US$37.9m).分析記事 • Nov 27These 4 Measures Indicate That Labiana Health (BME:LAB) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...お知らせ • Oct 29Labiana Health, S.A. to Report Q2, 2025 Results on Oct 30, 2025Labiana Health, S.A. announced that they will report Q2, 2025 results on Oct 30, 2025New Risk • Sep 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (6.0% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€31.0m market cap, or US$36.1m).New Risk • Jul 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.8% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€23.5m market cap, or US$27.6m).お知らせ • May 27Labiana Health, S.A., Annual General Meeting, Jun 26, 2025Labiana Health, S.A., Annual General Meeting, Jun 26, 2025. Location: av europa 34d, pozuelo de alarcon, madrid Spainお知らせ • Apr 13Labiana Health, S.A. to Report Fiscal Year 2024 Results on Apr 22, 2025Labiana Health, S.A. announced that they will report fiscal year 2024 results on Apr 22, 2025Breakeven Date Change • Nov 19Forecast breakeven date moved forward to 2024The 2 analysts covering Labiana Health previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €550.0k in 2024. Earnings growth of 99% is required to achieve expected profit on schedule.分析記事 • Nov 18Labiana Health (BME:LAB) Has No Shortage Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Jun 08Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€16.0m market cap, or US$17.3m).New Risk • Sep 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (€9.24m market cap, or US$9.78m).株主還元LABES PharmaceuticalsES 市場7D3.8%3.2%3.1%1Y100.6%10.8%25.7%株主還元を見る業界別リターン: LAB過去 1 年間で10.8 % の収益を上げたSpanish Pharmaceuticals業界を上回りました。リターン対市場: LAB過去 1 年間で25.7 % の収益を上げたSpanish市場を上回りました。価格変動Is LAB's price volatile compared to industry and market?LAB volatilityLAB Average Weekly Movement10.7%Pharmaceuticals Industry Average Movement3.7%Market Average Movement3.8%10% most volatile stocks in ES Market6.8%10% least volatile stocks in ES Market1.0%安定した株価: LABの株価は、 Spanish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: LABの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてSpanishの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1958394Manuel Ortegawww.labiana.comLabiana Health, S.A.は、スペイン、EU圏内、および国際的に、動物用およびヒト用の医薬品を開発、製造、販売、マーケティングしている。同社は、麻酔鎮静剤、抗感染症剤、抗炎症剤、抗寄生虫剤、ホルモン剤、栄養剤、代謝調整剤、ビタミン剤を提供している。また、無菌製剤、凍結乾燥製剤、生物学的製剤、Fosfomicina Labianaのブランド名でFosfomycin trometamolも提供している。さらに、受託開発・製造サービスも提供している。Labiana Health S.A.は1958年に設立され、スペインのポズエロ・デ・アラルコンに本拠を置く。もっと見るLabiana Health, S.A. 基礎のまとめLabiana Health の収益と売上を時価総額と比較するとどうか。LAB 基礎統計学時価総額€59.91m収益（TTM）€904.36k売上高(TTM)€71.67m63.0xPER（株価収益率0.8xP/SレシオLAB は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計LAB 損益計算書（TTM）収益€71.67m売上原価€31.00m売上総利益€40.67mその他の費用€39.77m収益€904.36k直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）0.11グロス・マージン56.74%純利益率1.26%有利子負債／自己資本比率980.9%LAB の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 20:06終値2026/05/26 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Labiana Health, S.A. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Iñigo Recio PascualGVC Gaesco ValoresAlfredo Echevarria OteguiLighthouse-IEAF Servicios de AnalisisLuis Esteban ArribasLighthouse-IEAF Servicios de Analisis
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$64.3m).
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €5.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 27x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 97% over the past three years.
お知らせ • Apr 18Labiana Health, S.A. to Report Fiscal Year 2025 Results on Apr 21, 2026Labiana Health, S.A. announced that they will report fiscal year 2025 results on Apr 21, 2026
New Risk • Apr 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€38.7m market cap, or US$45.5m).
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €4.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 68% over the past three years.
New Risk • May 19New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€55.4m market cap, or US$64.3m).
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment improves as stock rises 21%After last week's 21% share price gain to €5.80, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 27x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 97% over the past three years.
お知らせ • Apr 18Labiana Health, S.A. to Report Fiscal Year 2025 Results on Apr 21, 2026Labiana Health, S.A. announced that they will report fiscal year 2025 results on Apr 21, 2026
New Risk • Apr 13New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (7.7% average weekly change). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (17% increase in shares outstanding). Market cap is less than US$100m (€38.7m market cap, or US$45.5m).
Valuation Update With 7 Day Price Move • Mar 31Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €4.44, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 44% over the past three years.
Valuation Update With 7 Day Price Move • Mar 13Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €5.50, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 25x in the Pharmaceuticals industry in Spain. Total returns to shareholders of 68% over the past three years.
New Risk • Feb 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.2x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.7% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€31.9m market cap, or US$37.9m).
分析記事 • Nov 27These 4 Measures Indicate That Labiana Health (BME:LAB) Is Using Debt ExtensivelyWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
お知らせ • Oct 29Labiana Health, S.A. to Report Q2, 2025 Results on Oct 30, 2025Labiana Health, S.A. announced that they will report Q2, 2025 results on Oct 30, 2025
New Risk • Sep 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Spanish stocks, typically moving 6.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (6.0% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€31.0m market cap, or US$36.1m).
New Risk • Jul 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Share price has been volatile over the past 3 months (4.8% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (€23.5m market cap, or US$27.6m).
お知らせ • May 27Labiana Health, S.A., Annual General Meeting, Jun 26, 2025Labiana Health, S.A., Annual General Meeting, Jun 26, 2025. Location: av europa 34d, pozuelo de alarcon, madrid Spain
お知らせ • Apr 13Labiana Health, S.A. to Report Fiscal Year 2024 Results on Apr 22, 2025Labiana Health, S.A. announced that they will report fiscal year 2024 results on Apr 22, 2025
Breakeven Date Change • Nov 19Forecast breakeven date moved forward to 2024The 2 analysts covering Labiana Health previously expected the company to break even in 2025. New consensus forecast suggests the company will make a profit of €550.0k in 2024. Earnings growth of 99% is required to achieve expected profit on schedule.
分析記事 • Nov 18Labiana Health (BME:LAB) Has No Shortage Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Jun 08Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change). Market cap is less than US$100m (€16.0m market cap, or US$17.3m).
New Risk • Sep 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.78m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Market cap is less than US$10m (€9.24m market cap, or US$9.78m).
